0001140361-23-058659.txt : 20231220 0001140361-23-058659.hdr.sgml : 20231220 20231220163115 ACCESSION NUMBER: 0001140361-23-058659 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231214 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231220 DATE AS OF CHANGE: 20231220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Roivant Sciences Ltd. CENTRAL INDEX KEY: 0001635088 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981173944 STATE OF INCORPORATION: D0 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40782 FILM NUMBER: 231501680 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE, 2 CHURCH STREET CITY: HAMILTON HM11 STATE: D0 ZIP: HM11 BUSINESS PHONE: 441-295-5950 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 8-K/A 1 ef20017039_8ka.htm 8-K/A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


FORM 8-K/A


CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): December 14, 2023


Roivant Sciences Ltd.
(Exact Name of Registrant as Specified in Charter)

Bermuda
001-40782
98-1173944
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

7th Floor
50 Broadway
London SW1H 0DB
United Kingdom
(Address of Principal Executive Offices, and Zip Code)

+44 207 400-3347
Registrant’s Telephone Number, Including Area Code

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

  ☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  ☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
 
 Title of each class    Trading Symbol(s)    Name of each exchange on which registered
Common Shares, $0.0000000341740141 per share
  
ROIV
  
The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

EXPLANATORY NOTE

On December 14, 2023, Roivant Sciences Ltd. (the “Company”) filed with the Securities and Exchange Commission a Current Report on Form 8-K (the “Initial 8-K”) to disclose that it had completed its previously announced sale of Telavant Holdings, Inc. to Roche Holdings, Inc. (the “Transaction”). This Form 8-K/A amends the Initial 8-K to include the pro forma financial information of the Company giving effect to the completion of the Transaction required by Item 9.01(b) of Form 8-K.

Item 9.01.
Financial Statements and Exhibits.

(b) Pro Forma Financial Information.

The following unaudited pro forma condensed consolidated financial information of the Company, giving effect to the Transaction, is attached hereto as Exhibit 99.1 and is incorporated herein by reference:


 •
Unaudited Pro Forma Condensed Consolidated Balance Sheet as of September 30, 2023;

•
Unaudited Pro Forma Condensed Consolidated Statement of Operations for the Six Months Ended September 30, 2023; and

•
Unaudited Pro Forma Condensed Consolidated Statement of Operations for the Year Ended March 31, 2023.

(d) Exhibits.

Exhibit No.
  
Description of Exhibit
 
Unaudited Pro Forma Condensed Consolidated Financial Information of the Company
104
  
Cover Page Interactive Data File (embedded with Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ROIVANT SCIENCES LTD.
  
   
By:
/s/ Matt Maisak
  
 
Name:
Matt Maisak
  
 
Title:
Authorized Signatory
  
   
Dated: December 20, 2023
  


EX-99.1 2 ef20017039_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION
 
On December 14, 2023, Roivant Sciences Ltd. (“Roivant” or the “Company”) completed the previously announced sale (the “Transaction”) of all of the shares of capital stock it held in Telavant Holdings, Inc. (“Telavant”) to Roche Holdings, Inc. (“Roche” or the “Buyer”). The Transaction was made pursuant to a Stock Purchase Agreement dated October 22, 2023 (the “Purchase Agreement”) among the Company, Pfizer Inc. (“Pfizer”, and together with Roivant, the “Sellers”), Roche and Telavant. Telavant was jointly formed by Roivant and Pfizer in 2022 to develop and commercialize RVT-3101, an anti-TL1A antibody in development for ulcerative colitis (“UC”) and Crohn’s disease, in the United States and Japan. Roivant owned 75% of the issued and outstanding shares of common stock and preferred stock of Telavant and Pfizer owned the remaining 25%, in each case on an as-converted basis. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, Roche agreed to acquire from the Sellers all of the issued and outstanding shares of capital stock of Telavant. The Sellers received approximately $7.1 billion in cash at the closing of the Transaction, as set forth in the Purchase Agreement, and the Sellers will receive a milestone payment of $150 million in cash payable upon the initiation of a Phase 3 trial in UC. As described in more detail in the Purchase Agreement, the $7.1 billion cash received is paid to all of Telavant’s equity holders, including holders of restricted stock units, on a pro rata basis relative to their ownership of Telavant prior to the closing of the Transaction. Upon satisfaction of the milestone, cash received will be paid to all of the previously mentioned Telavant equity holders in the same fashion. At the closing of the Transaction, Roche acquired the full rights to further develop and manufacture RVT-3101 and commercialize it in the United States and Japan pending clinical and regulatory success. Roche is committed to starting a global Phase 3 trial for RVT-3101 as soon as possible to bring this promising therapy to patients suffering from inflammatory bowel disease. Outside of the United States and Japan, Pfizer holds commercialization rights. In addition, following the closing of the Transaction, Roche received an option to enter into a global collaboration with Pfizer on a next generation p40/TL1A directed bispecific antibody, currently in Phase 1.
 
The Telavant entity that was sold does not meet the definition of a business under accounting principles generally accepted in the United Stated (“U.S. GAAP”). Therefore, the Transaction is accounted for as the sale of nonfinancial assets. The following unaudited pro forma condensed consolidated financial statements are intended to show how the Transaction might have affected the historical financial statements of Roivant if the Transaction had been completed at an earlier time as indicated therein, and such unaudited pro forma condensed consolidated financial statements are derived from, and should be read in conjunction with, Roivant’s historical financial statements and notes thereto, as presented in its Quarterly Report on Form 10-Q and Annual Report on Form 10-K for the six months ended and the year ended September 30, 2023 and March 31, 2023, respectively. The unaudited pro forma condensed consolidated financial information has been prepared in accordance with Article 11 of Regulation S-X, as amended. The unaudited pro forma condensed consolidated balance sheet as of September 30, 2023, assumes the Transaction had occurred on September 30, 2023. The unaudited pro forma condensed consolidated statements of operations for the six months ended September 30, 2023, and the year ended March 31, 2023, give effect to the Transaction as if it had occurred as of April 1, 2022.
 
The transaction accounting adjustments to reflect the sale of Telavant in the unaudited pro forma condensed consolidated financial statements include:
 
•
the sale of the shares and the derecognition of assets and liabilities of Telavant pursuant to the Purchase Agreement;
 
•
adjustments required to record the estimated cash proceeds received in connection with the Transaction;
 
•
adjustments required to recognize the elimination of Pfizer’s noncontrolling interest in Telavant;
 
•
adjustments required to recognize the transaction costs arising from the Transaction;
 
•
adjustments required to recognize share-based compensation expense and severance expense incurred by Roivant in connection with the Transaction; and
 
•
adjustments required to recognize the estimated gain associated with the Transaction.
 
The contingent consideration of $150 million related to initiating the Phase 3 trial in UC is not reflected as transaction consideration in the unaudited pro forma condensed consolidated financial statements because it was not probable on the  Transaction closing date that the milestone would be achieved. The milestone will be recorded at the time, if and when it is probable of being achieved.
 
The unaudited pro forma condensed consolidated financial statements are presented for informational purposes only and are based upon estimates by Roivant’s management, which are based upon available information and certain assumptions that Roivant’s management believes are reasonable as of the date of this filing. Actual amounts could differ materially from these estimates. The unaudited pro forma condensed consolidated financial statements are not intended to be indicative of the actual financial position or results of operations that would have been achieved had the Transaction been consummated as of the periods indicated above, nor does it purport to indicate results which may be attained in the future. For example, these financial statements do not reflect any potential earnings or other impacts from the use of the proceeds from the sale or any synergies and dis-synergies that could result from the sale.
 
The unaudited pro forma condensed consolidated balance sheet as of September 30, 2023, and the unaudited pro forma condensed consolidated statement of operations for the six months ended September 30, 2023, and the year ended March 31, 2023, should be read in conjunction with the notes thereto.
Roivant Sciences Ltd.
Pro Forma Condensed Consolidated Balance Sheet
As of September 30, 2023
(Unaudited)
(Dollars in Thousands, except per share amounts)
   
Historical Roivant
    
Transaction Accounting Adjustments
      
Pro Forma Roivant
  
                     
Assets
                    
Current assets:
                    
Cash and cash equivalents
  
$
1,408,231
    
$
5,218,173
  
(a), (b)
  
$
6,626,404
  
Other current assets
    
143,396
      
(1,275
)
(a)
    
142,121
  
Total current assets
    
1,551,627
      
5,216,898
        
6,768,525
  
Property and equipment, net
    
24,477
      
-
        
24,477
  
Operating lease right-of-use assets
    
48,629
      
-
        
48,629
  
Investments measured at fair value
    
250,393
      
-
        
250,393
  
Intangible assets, net
    
140,621
      
-
        
140,621
  
Other assets
    
49,796
      
-
        
49,796
  
Total assets
  
$
2,065,543
    
$
5,216,898
      
$
7,282,441
  
                           
Liabilities and shareholders' equity
                          
Current liabilities:
                          
Accounts payable
    
44,123
      
-
        
44,123
  
Accrued expenses
    
152,923
      
(29,236
)
(a), (c)
    
123,687
  
Operating lease liabilities
    
10,903
      
-
        
10,903
  
Current portion of long-term debt
    
48,998
      
-
        
48,998
  
Other current liabilities
    
8,599
      
-
        
8,599
  
Total current liabilities
    
265,546
      
(29,236
)
      
236,310
  
Liability instruments measured at fair value
    
31,114
      
(248
)
(a)
    
30,866
  
Operating lease liabilities, noncurrent
    
48,630
      
-
        
48,630
  
Long-term debt, net of current portion
    
389,445
      
-
        
389,445
  
Other liabilities
    
5,175
      
-
        
5,175
  
Total liabilities
    
739,910
      
(29,484
)
      
710,426
  
Commitments and contingencies
                          
Shareholders' equity:
                          
Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 800,792,365 and 760,143,393 shares issued and outstanding at September 30, 2023 and March 31, 2023, respectively
    
-
      
-
        
-
  
Preferred stock
    
-
      
-
        
-
  
Additional paid-in capital
    
5,320,503
      
-
        
5,320,503
  
Accumulated deficit
    
(4,368,897
)
    
5,333,882
  
(d)
    
964,985
  
Accumulated other comprehensive loss
    
(3,072
)
    
-
        
(3,072
)
Shareholders’ equity attributable to Roivant Sciences Ltd.
    
948,534
      
5,333,882
        
6,282,416
  
Noncontrolling interests
    
377,099
      
(87,500
)
(e)
    
289,599
  
Total shareholders' equity
    
1,325,633
      
5,246,382
        
6,572,015
  
Total liabilities and shareholders' equity
  
$
2,065,543
    
$
5,216,898
      
$
7,282,441
  


See accompanying notes to unaudited pro forma condensed consolidated financial information.
Roivant Sciences Ltd.
Pro Forma Condensed Consolidated Statement of Operations
For the six months ended September 30, 2023
(Unaudited)
(Dollars in Thousands, except per share amounts)
                     
   
Historical Roivant
    
Transaction Accounting
Adjustments
      
Pro Forma Roivant
  
                     
Revenue:
                    
Product revenue, net
  
$
35,083
    
$
-
      
$
35,083
  
License, milestone and other revenue
    
23,642
      
-
        
23,642
  
Revenue, net
    
58,725
      
-
        
58,725
  
Operating expenses:
                          
Cost of revenues
    
7,480
      
-
        
7,480
  
Research and development
    
257,117
      
(36,089
)
(f)
    
221,028
  
Acquired in-process research and development
    
26,450
      
-
        
26,450
  
Selling, general and administrative
    
320,545
      
(7,745
)
(f)
    
312,800
  
Total operating expenses
    
611,592
      
(43,834
)
      
567,758
  
Loss from operations
    
(552,867
)
    
43,834
        
(509,033
)
Change in fair value of investments
    
53,413
      
-
        
53,413
  
Change in fair value of debt and liability instruments
    
76,045
      
-
        
76,045
  
Gain on deconsolidation of subsidiaries
    
(17,354
)
    
-
        
(17,354
)
Interest income
    
(31,014
)
    
-
        
(31,014
)
Interest expense
    
18,159
      
-
        
18,159
  
Other expense, net
    
1,338
      
-
        
1,338
  
Loss before income taxes
    
(653,454
)
    
43,834
        
(609,620
)
Income tax expense
    
5,509
      
-
        
5,509
  
Net loss
    
(658,963
)
    
43,834
        
(615,129
)
Net loss attributable to noncontrolling interests
    
(62,820
)
    
-
        
(62,820
)
Net loss attributable to Roivant Sciences Ltd.
  
$
(596,143
)
  
$
43,834
      
$
(552,309
)
                           
Net Loss per Common Share
                          
Weighted average shares outstanding, basic and diluted
    
764,780,630
                
764,780,630
  
Basic and diluted net loss per common share
  
$
(0.78
)
             
$
(0.72
)

See accompanying notes to unaudited pro forma condensed consolidated financial information.
Roivant Sciences Ltd.
Pro Forma Condensed Consolidated Statement of Operations
For the year ended March 31, 2023
(Unaudited)
(Dollars in Thousands, except per share amounts)
 
                     
   
Historical Roivant
    
Transaction Accounting
Adjustments
      
Pro Forma Roivant
  
                     
Revenue:
                    
Product revenue, net
  
$
28,011
    
$
-
      
$
28,011
  
License, milestone and other revenue
    
33,269
      
-
        
33,269
  
Revenue, net
    
61,280
      
-
        
61,280
  
Operating expenses:
                          
Cost of revenues
    
13,128
      
-
        
13,128
  
Research and development
    
525,215
      
(99,577
)
(f)
    
425,638
  
Acquired in-process research and development
    
97,749
      
-
        
97,749
  
Selling, general and administrative
    
600,506
      
13,263
  
(f), (g)
    
613,769
  
Total operating expenses
    
1,236,598
      
(86,314
)
      
1,150,284
  
Gain on sale of Telavant net assets
    
-
      
5,333,882
  
(h)
    
5,333,882
  
Income (loss) from operations
    
(1,175,318
)
    
5,420,196
        
4,244,878
  
Change in fair value of investments
    
20,815
      
-
        
20,815
  
Change in fair value of debt and liability instruments
    
78,001
      
-
        
78,001
  
Gain on deconsolidation of subsidiaries
    
(29,276
)
    
-
        
(29,276
)
Interest income
    
(32,184
)
    
-
        
(32,184
)
Interest expense
    
27,968
      
-
        
27,968
  
Other income, net
    
(15,808
)
    
-
        
(15,808
)
Income (loss) from continuing operations before income taxes
    
(1,224,834
)
    
5,420,196
        
4,195,362
  
Income tax expense
    
5,190
      
-
        
5,190
  
Income (loss) from continuing operations, net of tax
    
(1,230,024
)
    
5,420,196
        
4,190,172
  
Net loss attributable to noncontrolling interests
    
(106,433
)
    
-
        
(106,433
)
Net income (loss) from continuing operations attributable to Roivant Sciences Ltd.
  
$
(1,123,591
)
  
$
5,420,196
      
$
4,296,605
  
                           
Earnings per Common Share
                          
Weighted average shares outstanding, basic and diluted
    
712,791,115
                
712,791,115
  
Basic and diluted net income (loss) from continuing operations per common share
  
$
(1.58
)
             
$
6.03
  
 
See accompanying notes to unaudited pro forma condensed consolidated financial information.
Roivant Sciences Ltd.
Notes to Pro Forma Condensed Consolidated Financial Statements
(Unaudited)
 
Note 1 — Basis of Presentation
The pro forma financial information is prepared pursuant to Article 11 of Regulation S-X. The pro forma adjustments are described in the accompanying notes and are based upon and derived from information and assumptions available at the time of the filing of the Current Report on Form 8-K to which this pro forma financial information is attached.
The pro forma financial information is based on financial statements prepared in accordance with U.S. GAAP, which is subject to change and interpretation. The pro forma financial information is based on and derived from the Company’s historical condensed consolidated financial statements, adjusted for certain transaction accounting adjustments. Actual adjustments, however, may differ materially from the information presented. The pro forma adjustments do not include allocations of corporate costs, as those are not directly attributable to the Transaction. The pro forma adjustments also do not include management adjustments to reflect any potential dis-synergy costs or benefits that may result from the realization of future cost savings in connection with the Transaction as management does not believe presenting such adjustments would enhance an understanding of the pro forma effects thereof. In addition, the pro forma financial information is based upon available information and assumptions that management considers to be reasonable, and such assumptions have been made solely for purposes of developing such pro forma financial information for illustrative purposes in compliance with the disclosure requirements of the U.S Securities and Exchange Commission. The pro forma financial information is not necessarily indicative of what the financial position or results of operations would have actually been had the Transaction occurred on the dates indicated. In addition, the pro forma financial information should not be considered to be indicative of the Company’s future consolidated financial performance and results of operations.
 
Note 2 — Pro Forma Adjustments
 
The unaudited pro forma condensed consolidated financial statements reflect the following notes and adjustments:
 
  (a)
Sale of Telavant shares and derecognition of the assets and liabilities of Telavant pursuant to the Purchase Agreement.

(b)
Recognition of $5.2 billion of cash received by Roivant at the closing of the Transaction.

(c)
Elimination of $3.3 million of transaction expenses accrued on Roivant’s condensed consolidated balance sheet as of September 30, 2023, which were subsequently paid by Roche in the Transaction.

(d)
Recognition of a $5.3 billion gain on the Transaction allocated to Roivant, assuming the Transaction had occurred on September 30, 2023 (see calculation below). The $150 million contingent milestone payment is not included in the gain because it was not probable on the Transaction closing date that the milestone would be achieved. It will be recognized subsequently, if and when the milestone is probable of being achieved. The gain on disposal qualifies under the substantial shareholding exemption of UK corporate tax law.

   
(in millions)
  
Cash received from Buyer Upon Closing
  
$
5,234.4
  
Add: Accrued Transaction Expenses Paid on Behalf of Roivant
  

3.3
  
Add: Carrying Amount of Pfizer’s Noncontrolling Interest Derecognized
  

87.5
  
Add: Carrying Amount of Net Liabilities Relieved
  

8.7
  
Gain on Sale of Telavant Net Assets
  
$
5,333.9
  
 

 		(e)
Elimination of Pfizer’s noncontrolling interest in Telavant as of September 30, 2023. There is no impact to net income (loss) attributable to noncontrolling interests in the income statement.

(f)
Derecognition of Telavant expenses for the year ended March 31, 2023, and the six months ended September 30, 2023.

(g)
Recognition of expenses incurred as a result of the Transaction, including $6.7 million of transaction expenses directly attributable to the Transaction that were incurred subsequent to September 30, 2023, recognition of $8.7 million of share-based compensation expense for Telavant employee restricted stock units that were vested for accounting purposes in accordance with the original grant agreement terms as of the Transaction date, and recognition of $192 thousand of expense for severance payments made in accordance with the terms of Telavant employees’ original employment agreements.

(h)
Recognition of a $5.3 billion gain on the Transaction allocated to Roivant (see note (d)). The Company notes that the pro forma condensed consolidated statement of operations for the fiscal year ended March 31, 2023, assumes that the Transaction occurred as of April 1, 2022. However, Telavant did not exist until November 14, 2022. Hence, the gain presented in the pro forma condensed consolidated statement of operations for the fiscal year ended March 31, 2023, is the same gain on sale calculated for the pro forma condensed consolidated balance sheet as of September 30, 2023 (which assumes that the Transaction occurred as of September 30, 2023).
 
EX-101.SCH 3 roiv-20231214.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 roiv-20231214_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 roiv-20231214_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document and Entity Information
Dec. 14, 2023
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag false
Document Period End Date Dec. 14, 2023
Entity File Number 001-40782
Entity Registrant Name Roivant Sciences Ltd.
Entity Central Index Key 0001635088
Entity Incorporation, State or Country Code D0
Entity Tax Identification Number 98-1173944
Entity Address, Address Line One 7th Floor
Entity Address, Address Line Two 50 Broadway
Entity Address, City or Town London
Entity Address, Country GB
Entity Address, Postal Zip Code SW1H 0DB
City Area Code 207
Local Phone Number 400-3347
Title of 12(b) Security Common Shares, $0.0000000341740141 per share
Trading Symbol ROIV
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 7 ef20017039_8ka_htm.xml IDEA: XBRL DOCUMENT 0001635088 2023-12-14 2023-12-14 false 0001635088 8-K/A 2023-12-14 Roivant Sciences Ltd. D0 001-40782 98-1173944 7th Floor 50 Broadway London SW1H 0DB GB 207 400-3347 false false false false Common Shares, $0.0000000341740141 per share ROIV NASDAQ true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 24 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://roivant.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20017039_8ka.htm roiv-20231214.xsd roiv-20231214_lab.xml roiv-20231214_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20017039_8ka.htm": { "nsprefix": "roiv", "nsuri": "http://roivant.com/20231214", "dts": { "inline": { "local": [ "ef20017039_8ka.htm" ] }, "schema": { "local": [ "roiv-20231214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "roiv-20231214_lab.xml" ] }, "presentationLink": { "local": [ "roiv-20231214_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://roivant.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20231214to20231214", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20017039_8ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20231214to20231214", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20017039_8ka.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://roivant.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001140361-23-058659-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-058659-xbrl.zip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end